Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 1998

View Archived Issues

Techniclone advancing development of Tumor Necrosis Therapy into phase II

PEG-hirudin more effective than heparin in patients with acute coronary syndromes

Hemosol blood substitute to enter phase II clinical trials in U.S. for CABG

AEterna isolates molecule exhibiting anti-MMP activity

Positive results reported from clinical trial of Remune

SNAP-8719: a valuable tool for studying alpha1D-adrenoceptor function

Xoma: Q2 1998 highlights

Medarex receives milestone payment from Merck KGaA

Novartis announces VALIANT trial

CAT demonstrates value of ProxiMol technology

AnorMED initiates phase I clinical trial of AMD-3100

Betaseron to receive fast track review in Canada

Lamotrigine approved for new indication in the U.S.: Lennox-Gastaut syndrome

Cambridge NeuroScience announces advances in MS program

AutoImmune: Q2 1998 highlights

P&U to market Glyset in U.S., Canada and several other countries

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Potent new antimalarial trioxanes developed at Johns Hopkins

L-168721: potent, nonpeptide GH secretagogue

Novartis describes search for potent and selective CDK1/CDK2 inhibitors

Lead candidate for botulinum neurotoxin poisoning: ICD-1578

Banyu presents urea derivatives with NPY receptor-antagonist activity

Inhibitors of NOS developed at Pfizer

Anticonvulsant benzamides prepared at SKB

Zeneca patents new peptides for autoimmune/inflammatory disorders

Merck & Co. claims glucagon antagonists, cytokine inhibitors

Compounds interacting with nicotinic receptors for cognitive and memory deficits

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...